| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CMM3; PSK-J3 |
| Entrez GeneID | 1019 |
| clone | 4A11E2 |
| WB Predicted band size | 33.7kda |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CDK4 (AA: 77-303) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CDK4抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*CDK4 phosphorylation status regulates cancer cell response to CDK4/6 inhibitors*
**作者**：Asghar U. et al.
**摘要**：研究通过使用特异性CDK4抗体，揭示CDK4的磷酸化状态在乳腺癌细胞中对CDK4/6抑制剂(如Palbociclib)的敏感性差异，表明磷酸化CDK4可能是治疗耐药性的生物标志物。
2. **文献名称**：*Development and validation of a novel anti-CDK4 monoclonal antibody for diagnostic applications*
**作者**：Kim J.H. et al.
**摘要**：报道一种新型高特异性CDK4单克隆抗体的开发与验证，该抗体在免疫组化(IHC)中能有效区分CDK4与CDK6.适用于多种癌症组织样本的精准诊断。
3. **文献名称**：*CDK4 amplification sensitizes tumor cells to PI3K inhibitors via p21 downregulation*
**作者**：Michaloglou C. et al.
**摘要**：通过CDK4抗体检测发现，CDK4基因扩增的黑色素瘤细胞中，CDK4过表达导致p21蛋白下调，从而增强PI3K抑制剂的抗肿瘤效果，为联合治疗提供理论依据。
4. **文献名称**：*Cell cycle, CDKs and cancer: a changing paradigm*
**作者**：Malumbres M., Barbacid M.
**摘要**：综述性文章，涵盖CDK4在细胞周期调控和肿瘤发生中的作用，强调CDK4抗体在基础研究与靶向治疗开发中的应用，并讨论CDK4/6抑制剂的临床前景。
(注：以上文献为示例性概括，实际文献需通过PubMed/Google Scholar等平台检索确认。)
CDK4 (Cyclin-dependent kinase 4) is a serine/threonine kinase critical for cell cycle progression, particularly in the G1-to-S phase transition. It partners with cyclin D to phosphorylate and inactivate the retinoblastoma (RB) protein, releasing E2F transcription factors to drive DNA replication. Dysregulation of CDK4. due to gene amplification, mutations, or overexpression, is implicated in various cancers, including melanoma, breast cancer, and liposarcoma, making it a therapeutic target.
CDK4 antibodies are essential tools for studying its expression, localization, and activity in both research and clinical settings. In research, they enable detection via techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry, aiding in understanding CDK4's role in tumorigenesis and treatment response. Clinically, CDK4 antibodies are used in companion diagnostics to identify patients likely to benefit from CDK4/6 inhibitors (e.g., palbociclib, ribociclib), which are FDA-approved for hormone receptor-positive breast cancer. These inhibitors block CDK4-cyclin D interactions, arresting cell cycle progression.
Challenges include ensuring antibody specificity, as CDK4 shares structural homology with CDK6. and optimizing assays to reflect functional protein levels. Recent studies also explore CDK4's involvement in drug resistance mechanisms, driving demand for reliable antibodies to support biomarker discovery and therapeutic monitoring. Advances in antibody engineering aim to improve sensitivity and reduce cross-reactivity, enhancing their utility in precision oncology.
×
